MindBio Therapeutics Advances Women’s Health and Depression Treatment Trials

MindBio Therapeutics Corp., a biopharmaceutical company focusing on microdosing treatments for mental health, has recently highlighted its innovative women's health trials aimed at treating Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD) with fewer side effects. The trials utilize MB22001, a proprietary form of Lysergic Acid Diethylamide (LSD), enabling patients to safely microdose at home.

MindBio has successfully completed a Phase 2A trial for Major Depressive Disorder using MB22001, evidencing significant symptom reduction and remission rates by the eighth week of treatment. The forthcoming secondary data set to be released will provide further insights into the post-treatment effects of MB22001, potentially solidifying its efficacy before advancing to Phase 3 trials.

Justin Hanka, CEO of MindBio, expressed optimism about the ongoing research and its implications for future treatment modalities in mental health, particularly in preparing for the next stages of the company's growth.